Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 3/2017

01-08-2017 | Original Article

Patient acceptability and experiences of therapeutic switching of proton pump inhibitors within the National Preferred Drugs initiative in Ireland

Authors: G. O’Connor, D. O’Keeffe, C. Darker, B. O’Shea

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2017

Login to get access

Abstract

Introduction

A ‘Preferred Drugs’ initiative was introduced into Ireland in 2013. This identified a single recommended drug to be prescribed to patients requiring treatment from a particular class of drugs.

Aims

This study investigates how patients on established proton pump inhibitor (PPI) therapy experienced the therapeutic switching of their medication to the ‘preferred drug’, and the extent to which they regarded it as an acceptable practice.

Methods

The experiences of 61 patients on established proton pump inhibitor (PPI) therapy were sought before and after their drug was switched to the ‘preferred drug’.

Results

Eighty per cent of patients were happy to switch medications. When asked for their opinions on medications in general, 71% felt doctors should prescribe the least expensive medication, 84% agreed that all licensed medications were safe while 67% felt their GP changing medication for cost reasons was safe. After 8 weeks, 20% of patients had switched back to their old PPI. When asked how they felt about their medication change, 74% felt happy or pleased.

Conclusions

The majority of patients in our study were satisfied to have their medication switched. However, prescribers should be mindful that 1 in 5 patients encountered problems as a result of the switching process.
Appendix
Available only for authorised users
Literature
1.
go back to reference FDA Orange Book, preface to the 36 edn., National Archives and Records Administration, Office of the Federal Register FDA Orange Book, preface to the 36 edn., National Archives and Records Administration, Office of the Federal Register
2.
go back to reference Lu CY, Ross-Degnan D, Soumerai SB, Pearson SA (2008) Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature—2001–2007. BMC Health Serv Res 8:75CrossRefPubMedPubMedCentral Lu CY, Ross-Degnan D, Soumerai SB, Pearson SA (2008) Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature—2001–2007. BMC Health Serv Res 8:75CrossRefPubMedPubMedCentral
6.
go back to reference Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K (2012) Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res 12:408CrossRefPubMedPubMedCentral Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K (2012) Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res 12:408CrossRefPubMedPubMedCentral
9.
go back to reference Heikkila et al (2007) Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy 82:366–374CrossRefPubMed Heikkila et al (2007) Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy 82:366–374CrossRefPubMed
10.
go back to reference Landon BE, Reschovsky JD, Blumenthal D (2004) Physicians’ views of formularies: implications for medicare drug benefit design. Health Aff 23:218–226CrossRef Landon BE, Reschovsky JD, Blumenthal D (2004) Physicians’ views of formularies: implications for medicare drug benefit design. Health Aff 23:218–226CrossRef
11.
go back to reference Dunne S, Shannon B, Dunne C, Cullen W (2014) Patient perceptions of generic medicines: a mixed-methods study. Patient Patient Centred Outcomes Res 7(2):177CrossRef Dunne S, Shannon B, Dunne C, Cullen W (2014) Patient perceptions of generic medicines: a mixed-methods study. Patient Patient Centred Outcomes Res 7(2):177CrossRef
12.
13.
go back to reference Keenum et al (2012) Generic medications for you, but brand-name medications for me. Res Soc Adm Pharm 8(6):574–578CrossRef Keenum et al (2012) Generic medications for you, but brand-name medications for me. Res Soc Adm Pharm 8(6):574–578CrossRef
14.
go back to reference Mc Donagh MS, Carson S, Thakura S (2009) Drug Class Review Proton Pump Inhibitors. Final Report Update 5. Oregon Health and Science University. 2009 May Mc Donagh MS, Carson S, Thakura S (2009) Drug Class Review Proton Pump Inhibitors. Final Report Update 5. Oregon Health and Science University. 2009 May
15.
go back to reference OECD Health at a Glance 2015. http://www.oecd.org/ireland/Health-at-a-Glance-2015-Key-Findings-IRELAND.pdf. Accessed February 2015 OECD Health at a Glance 2015. http://​www.​oecd.​org/​ireland/​Health-at-a-Glance-2015-Key-Findings-IRELAND.​pdf.​ Accessed February 2015
16.
go back to reference Crawford MJ, Rutter D, Manley C, Weaver T, Bhui K, Fulop N, Tyrer P (2002) Systematic review of involving patients in the planning and development of health care. BMJ 325:1263CrossRefPubMedPubMedCentral Crawford MJ, Rutter D, Manley C, Weaver T, Bhui K, Fulop N, Tyrer P (2002) Systematic review of involving patients in the planning and development of health care. BMJ 325:1263CrossRefPubMedPubMedCentral
17.
go back to reference Epstein RM, Fiscella K, Lesser CS, Stange KC (2010) Why the nation needs a policy push on Patient-Centered Health Care. Health Aff 29(8):1489–1495CrossRef Epstein RM, Fiscella K, Lesser CS, Stange KC (2010) Why the nation needs a policy push on Patient-Centered Health Care. Health Aff 29(8):1489–1495CrossRef
18.
go back to reference Happe LE, Clark D, Holliday E, Young T (2014) A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm 20(7):677–684PubMed Happe LE, Clark D, Holliday E, Young T (2014) A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm 20(7):677–684PubMed
19.
go back to reference Godman et al (2012) Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. Generics Biosimilars Initiat J (GaBI J) 1(2):69–83CrossRef Godman et al (2012) Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. Generics Biosimilars Initiat J (GaBI J) 1(2):69–83CrossRef
20.
go back to reference Sinnott SJ, Guinane M, Whelton H, Byrne S (2013) Is 50 cent the price of the optimal copayment?—a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly funded health system in Ireland. BMC Health Serv Res 13:16CrossRefPubMedPubMedCentral Sinnott SJ, Guinane M, Whelton H, Byrne S (2013) Is 50 cent the price of the optimal copayment?—a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly funded health system in Ireland. BMC Health Serv Res 13:16CrossRefPubMedPubMedCentral
22.
go back to reference Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K (2005) What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 14:341–348CrossRefPubMed Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K (2005) What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 14:341–348CrossRefPubMed
23.
go back to reference Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A (2009) Consumers’ views on generic medicines: a review of the literature. J Pharm Pract 17(2):79–88 Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A (2009) Consumers’ views on generic medicines: a review of the literature. J Pharm Pract 17(2):79–88
24.
go back to reference Sinnott SJ, Normand C, Byrne S, Woods N, Whelton H (2015) Copayments for prescription medicines on a public health insurance scheme in Ireland. Pharmacoepidemiol Drug Saf. doi:10.1002/pds.3917 PubMed Sinnott SJ, Normand C, Byrne S, Woods N, Whelton H (2015) Copayments for prescription medicines on a public health insurance scheme in Ireland. Pharmacoepidemiol Drug Saf. doi:10.​1002/​pds.​3917 PubMed
25.
go back to reference Sachs G, Shin JM, Howden CW (2006) Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23(s2):2–8CrossRefPubMed Sachs G, Shin JM, Howden CW (2006) Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23(s2):2–8CrossRefPubMed
26.
go back to reference Castell DO, Kahrilas PJ, Richter JE et al (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol CR 97(3):575–583CrossRef Castell DO, Kahrilas PJ, Richter JE et al (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol CR 97(3):575–583CrossRef
27.
go back to reference Fennerty MB, Johanson JF, Hwang C, Sostek M (2005) Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 21(4):455–463CrossRefPubMed Fennerty MB, Johanson JF, Hwang C, Sostek M (2005) Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 21(4):455–463CrossRefPubMed
28.
go back to reference Howden CW, Ballard EDI, Robieson W (2002) Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Investig 22(2):99–109CrossRefPubMed Howden CW, Ballard EDI, Robieson W (2002) Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Investig 22(2):99–109CrossRefPubMed
29.
go back to reference Horn SD et al (1996) Intended and unintended consequences of HMO cost-containment strategies: results from the managed care outcomes project. Am J Manag Care 2(3):253–264 Horn SD et al (1996) Intended and unintended consequences of HMO cost-containment strategies: results from the managed care outcomes project. Am J Manag Care 2(3):253–264
30.
go back to reference Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO (1996) Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 57(2):67–71PubMed Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO (1996) Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 57(2):67–71PubMed
31.
go back to reference Ruhe HG, Huyser J, Swinkels JA, Schene AH (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836–1855CrossRefPubMed Ruhe HG, Huyser J, Swinkels JA, Schene AH (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836–1855CrossRefPubMed
Metadata
Title
Patient acceptability and experiences of therapeutic switching of proton pump inhibitors within the National Preferred Drugs initiative in Ireland
Authors
G. O’Connor
D. O’Keeffe
C. Darker
B. O’Shea
Publication date
01-08-2017
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 3/2017
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-016-1535-2

Other articles of this Issue 3/2017

Irish Journal of Medical Science (1971 -) 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine